| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_431309bc8dab94a0ee0e2aa5aeacd48d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2839 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2018-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f850e9d92c498bd1e5200853dbb35974
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35286f631e3918e1f18a661f2b92b16c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dea2413954152853625f8da5c1e0533f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ac38142fe108f72f4dea201b4520b56 |
| publicationDate |
2019-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019084335-A1 |
| titleOfInvention |
EXTENDED INTERVAL DOSAGE OF NATALIZUMAB |
| abstract |
In some embodiments, the invention provides methods for reducing the risk of developing progressive multifocal leukemia (PML) in patients receiving natalizumab therapy by switching to an extended-interval dosing schedule (EPIC). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022104156-A1 |
| priorityDate |
2017-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |